IL1B, interleukin 1 beta, 3553

N. diseases: 1801; N. variants: 22
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE We found that MI triggered NLRP3 inflammasome activation leading to conversion of interleukin-1β (IL-1β) and IL-18 into their active mature forms in the heart, which could expand the infarct size and drive cardiac dysfunction. 31645662 2020
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE Cases had higher levels of IL-1Ra at all time-points leading up to first-time MI, and higher levels of IL-1Ra were associated with approximately 1.5-fold increased risk of MI, supporting the rationale to target IL-1 activation in order to reduce cardiovascular risk in PWH. 31077280 2020
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE Recently, the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) showed the successful anti-inflammatory benefit of canakinumab, a monoclonal antibody targeting interleukin-1ß (IL-1ß) toward major cardiovascular events (MACE) in patients with a previous myocardial infarction (MI). 31469975 2020
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE All in all, miR-132 inhibits cardiomyocyte apoptosis so as to ameliorate myocardial remodeling in rats with MI through IL-1β downregulation. 31621911 2020
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 GeneticVariation disease BEFREE The objective of the study is to assess the modulatory effect of IL-1 genotypes on risk mediated by Lp(a) METHODS: We assessed whether IL-1 genotypes modulate the effect of Lp(a) on major adverse cardiovascular events (cardiovascular death, myocardial infarction, and stroke/transient ischemic attack) and angiographically determined coronary artery disease (CAD). 29310992 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE Cardiac nerve sprouting after MI is associated in part with NF-κB activation in the PVN, and IL-1β is involved in the process. 31175933 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. 31652822 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE Accordingly, CANTOS trial using an interleukin-1 beta antibody confirmed that inflammatory cytokines contribute to the occurrence of myocardial infarction and cardiac death independent of changes in lipids. 30918936 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE Together, the data indicated that the knockdown of Mincle in microglia within the PVN prevents VAs by attenuating sympathetic hyperactivity and ventricular susceptibility, in part by inhibiting its downstream NLRP3/IL-1β axis following MI. 30353660 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE Furthermore, a recent Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial revealed the efficacy of IL-1β inhibition in preventing recurrent cardiovascular events in patients with MI. 30930410 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE In conclusion, these data highlight a key role for the IL-1R1/cardiac fibroblast signaling axis in regulating post-MI remodeling and provide support for the continued development of anti-IL-1 therapies for improving cardiac function after MI. 31393855 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE Inflammasome activation and IL-1β secretion are implicated in myocardial infarction (MI) and resultant heart failure; however, little is known about how macrophage lysosomes regulate these processes. 31672943 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE These randomized double-blind placebo-controlled data suggest that therapy with canakinumab, an interleukin-1β inhibitor, is related to a dose-dependent reduction in HHF and the composite of HHF or heart failure-related mortality in a population of patients with prior myocardial infarction and elevations in high-sensitivity C-reactive protein. 30586730 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE We further evaluated the inflammation, fibrosis of left atria (LA), and related signal pathways by RT-PCR, Western blot, and staining analysis.Compared to the MI group, fisetin treatment improved cardiac function, inhibited macrophage recruitment into the LA and production of IL-1β and TNF-α, and attenuated adverse atrial fibrosis following acute myocardial infarction (AMI). 31666455 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 GeneticVariation disease BEFREE IL-1β-511C/T gene polymorphism may be related to the risk of MI complicated with IS. 30542472 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. 30010800 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 AlteredExpression disease BEFREE Systemic administration of 2-deoxyglucose after rodent MI normalized the hyperpolarized [1-<sup>13</sup>C]lactate signal in healing myocardial segments at day 3 and also caused dose-dependent improvement in IL (interleukin)-1β expression in infarct tissue without impairing the production of key reparative cytokines. 29440071 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 AlteredExpression disease BEFREE A similar trend was identified for the expression of NF-κB, IL-1β and MMP-2, which was significantly increased in the MI group compared with that in the sham group (P<0.01), while it was significantly decreased in the MG and PDTC groups compared with that in the MI group (P<0.01). 30112065 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 AlteredExpression disease BEFREE Transcript levels of the pro-inflammatory cytokines interleukin-6 and interleukin-1β were upregulated in hearts of vehicle treated animals compared to mice without MI. 29169754 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed that antagonism of interleukin (IL)-1β reduces coronary heart disease in patients with a previous myocardial infarction and evidence of systemic inflammation, indicating that pathways required for IL-1β secretion increase cardiovascular risk. 29588315 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 AlteredExpression disease BEFREE With the injection of neutralizing antibodies against IL-1β, control mice and MPGKO mice had comparable cardiac function and expression of inflammatory genes after MI. 29800789 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE Immunohistochemistry and Western blotting showed that Minocycline reduced the expressions of inflammatory factors, NF-κB and IL-1β, etc., in myocardial cells after myocardial infarction. 29136949 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 AlteredExpression disease BEFREE Elevated levels of IL-1β are associated with adverse remodeling, and inhibition of IL-1 signaling after MI results in improved contractile function. 28111350 2017
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 GeneticVariation disease BEFREE HC shows the strongest effect on risk of MI in addition to HTN; gender and smoking status while drinking status shows protective effect on MI. rs16944 (gene IL-1β) and rs17222772 (gene ALOX) increase the risks of HC, while rs17231896 (gene CETP) has protective effects on HC either with or without the clinical, behavioral, demographic factors with different effect sizes that may indicate the existence of moderate or modifiable effects. 28906356 2017
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.600 Biomarker disease BEFREE In conclusion, our data indicate that IL-1β-511TT/CC influence on the risk of myocardial infarction and ischemic stroke at young age through NF-κB, iNOS, MMP-2 and Bax. 26823694 2015